{'fraction_non_alphanumeric': 0.036641929499072357, 'fraction_numerical': 0.018089053803339517, 'mean_word_length': 5.825949367088608, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

In this double‐blind, randomized, placebo‐controlled crossover study, the authors investigated the initial time course of effects of isosorbide‐5‐mononitrate (IS‐5‐MN) on hemodynamic parameters in 15 healthy male volunteers after administering a single oral dose of either an immediate‐release formulation (IS‐5‐MN 20 mg) or of a sustained‐release formulation (IS‐5‐MN 50 mg). The latter formulation released 15 mg IS‐5‐MN immediately, while 35 mg of the dose was sustained release. The onset of effect on the a/b‐ratio of the finger pulse curve (20 minutes after administration) and on heart rate following orthostatic challenge (30 minutes) was not different following ingestion of either the immediate‐release or the sustained‐release formulation. Only the systolic blood pressure following orthostatic challenge was affected earlier after ingestion of the immediate‐release form of IS‐5‐MN (10 vs. 30 minutes). There was no statistically significant difference in the maximum effect on the measured hemodynamic parameters between the two formulations. There was no significant difference with respect to the effect per dose between both of the active treatments (i.e., IS‐5‐MN 20 mg immediate release and IS‐5‐MN 50 mg sustained release) within 6 hours after administration. The hemodynamic findings were consistent with the observed rates of the increase of plasma concentrations of IS‐5‐MN following both formulations. Thus, the administration of the sustained‐release formulation of IS‐5‐MN 50 mg caused similar maximum effects when compared with an immediate‐release formulation (20 mg). While the onset of effect of IS‐5‐MN on the a/b‐ratio of the finger pulse curve and on heart rate following orthostasis was similar after administration of either the immediate‐ or the sustained‐release formulation, the onset of effect of the sustained‐release formulation on systolic blood pressure orthostasis was determined slightly later. However, the latter difference seems to be of minor clinical relevance.